메뉴 건너뛰기




Volumn 16, Issue SUPPL. 1, 2010, Pages 2-6

Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue

Author keywords

Clinical trial; Efficacy; Haemophilia A; PEGylated liposomes; rFVIII; Safety

Indexed keywords

BAY 79 4979; BAY 79 4980; GLYCEROPHOSPHOLIPID; LIPOSOME; LONG ACTING DRUG; MACROGOL; OLEOYLPALMITOYLLECITHIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE; UNCLASSIFIED DRUG;

EID: 73949135703     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02155.x     Document Type: Review
Times cited : (26)

References (26)
  • 2
    • 0033432718 scopus 로고    scopus 로고
    • Assessing health-related quality-of-life in individuals with haemophilia
    • Miners AH, Sabin CA, Tolley KH. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999, 5:378-85.
    • (1999) Haemophilia , vol.5 , pp. 378-385
    • Miners, A.H.1    Sabin, C.A.2    Tolley, K.H.3
  • 3
    • 34547757915 scopus 로고    scopus 로고
    • Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
    • Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
    • (2007) N Engl J Med , vol.357 , pp. 535-544
    • Manco-Johnson, M.J.1    Abshire, T.C.2    Shapiro, A.D.3
  • 4
    • 73949143119 scopus 로고    scopus 로고
    • Cost of care of haemophilia with inhibitors
    • Oct 21 [Epub ahead of print]
    • Di MinnoMND, Di MinnoG, Di CapuaM, Cerbone AM, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia 2009, Oct 21 [Epub ahead of print]
    • (2009) Haemophilia
    • Di, M.1    Di, M.2    Di, C.3    Cerbone, A.M.4    Coppola, A.5
  • 5
    • 33646147385 scopus 로고    scopus 로고
    • Strategies towards a longer acting factor VIII
    • Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006, 12(Suppl. 3):42-51.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 3 , pp. 42-51
    • Saenko, E.L.1    Pipe, S.W.2
  • 6
    • 73949083366 scopus 로고    scopus 로고
    • Peg-interferon in acute and chronic hepatitis C: a review
    • May 19 [Epub ahead of print]
    • Palumbo E. Peg-interferon in acute and chronic hepatitis C: a review. Am J Ther 2009, May 19 [Epub ahead of print]
    • (2009) Am J Ther
    • Palumbo, E.1
  • 7
    • 34248658822 scopus 로고    scopus 로고
    • Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol
    • Takagi A, Yamashita N, Yoshioka T. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. J Control Release 2007, 119:271-8.
    • (2007) J Control Release , vol.119 , pp. 271-278
    • Takagi, A.1    Yamashita, N.2    Yoshioka, T.3
  • 8
    • 61549130569 scopus 로고    scopus 로고
    • Targeted drugs and nanomedicine: present and future
    • Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009, 15:153-72.
    • (2009) Curr Pharm Des , vol.15 , pp. 153-172
    • Debbage, P.1
  • 9
    • 1842735217 scopus 로고    scopus 로고
    • Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity
    • Pellequer Y, Ollivon M, Barratt G. Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity. Biomed Pharmacother 2004, 58:162-7.
    • (2004) Biomed Pharmacother , vol.58 , pp. 162-167
    • Pellequer, Y.1    Ollivon, M.2    Barratt, G.3
  • 10
    • 0033974941 scopus 로고    scopus 로고
    • Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes
    • Kedar E, Gur H, Babai I. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother 2000, 23:131-45.
    • (2000) J Immunother , vol.23 , pp. 131-145
    • Kedar, E.1    Gur, H.2    Babai, I.3
  • 11
    • 42649088435 scopus 로고    scopus 로고
    • A perspective on liposomal amphotericin B (AmBisome)
    • Richardson M, de Pauw B. A perspective on liposomal amphotericin B (AmBisome). Clin Microbiol Infect 2008, 14(Suppl. 4):1-4.
    • (2008) Clin Microbiol Infect , vol.14 , Issue.SUPPL. 4 , pp. 1-4
    • Richardson, M.1    de Pauw, B.2
  • 12
    • 59049085704 scopus 로고    scopus 로고
    • Review: doxorubicin delivery systems based on chitosan for cancer therapy
    • Tan ML, Choong PF, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 2009, 61:131-42.
    • (2009) J Pharm Pharmacol , vol.61 , pp. 131-142
    • Tan, M.L.1    Choong, P.F.2    Dass, C.R.3
  • 13
    • 0344420226 scopus 로고    scopus 로고
    • Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
    • Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-77.
    • (2003) Adv Drug Deliv Rev , vol.55 , pp. 1261-1277
    • Caliceti, P.1    Veronese, F.M.2
  • 15
    • 41349087510 scopus 로고    scopus 로고
    • Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin
    • Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008, 8:21-32.
    • (2008) Clin Lymphoma Myeloma , vol.8 , pp. 21-32
    • Soloman, R.1    Gabizon, A.A.2
  • 16
    • 58949099540 scopus 로고    scopus 로고
    • Novel therapies for cutaneous T-cell lymphomas
    • Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008, 8(Suppl. 5):S187-92.
    • (2008) Clin Lymphoma Myeloma , vol.8 , Issue.SUPPL. 5
    • Horwitz, S.M.1
  • 17
    • 20444503381 scopus 로고    scopus 로고
    • Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy
    • Baru M, Carmel-Goren L, Barenholz Y. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 2005, 93:1061-8.
    • (2005) Thromb Haemost , vol.93 , pp. 1061-1068
    • Baru, M.1    Carmel-Goren, L.2    Barenholz, Y.3
  • 18
    • 38349083504 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
    • Powell JS, Nugent DJ, Harrison JA. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008, 6:277-83.
    • (2008) J Thromb Haemost , vol.6 , pp. 277-283
    • Powell, J.S.1    Nugent, D.J.2    Harrison, J.A.3
  • 19
    • 51349110498 scopus 로고    scopus 로고
    • Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A
    • Spira J, Plyushch OP, Andreeva TA, Khametova RN. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008, 100:429-34.
    • (2008) Thromb Haemost , vol.100 , pp. 429-434
    • Spira, J.1    Plyushch, O.P.2    Andreeva, T.A.3    Khametova, R.N.4
  • 20
    • 70350500718 scopus 로고    scopus 로고
    • Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice
    • Epub 2009 Aug 4
    • Pan J, Liu T, Kim JY. Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice. Blood 2009, 114:2802-11. Epub 2009 Aug 4
    • (2009) Blood , vol.114 , pp. 2802-2811
    • Pan, J.1    Liu, T.2    Kim, J.Y.3
  • 21
    • 33845241302 scopus 로고    scopus 로고
    • Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes
    • Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006, 108:3668-73.
    • (2006) Blood , vol.108 , pp. 3668-3673
    • Spira, J.1    Plyushch, O.P.2    Andreeva, T.A.3    Andreev, Y.4
  • 22
    • 0032496674 scopus 로고    scopus 로고
    • The complement system in liposome clearance: can complement deposition be inhibited?
    • Bradley AJ, Devine DV. The complement system in liposome clearance: can complement deposition be inhibited? Adv Drug Deliv Rev 1998, 32:19-29.
    • (1998) Adv Drug Deliv Rev , vol.32 , pp. 19-29
    • Bradley, A.J.1    Devine, D.V.2
  • 23
    • 28244466864 scopus 로고    scopus 로고
    • Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity
    • Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-21.
    • (2005) Toxicology , vol.216 , pp. 106-121
    • Szebeni, J.1
  • 24
    • 51249103798 scopus 로고    scopus 로고
    • Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A
    • Martinowitz U, Lalezari S, Luboshitz J, Lubetsky A, Spira J. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A. Haemophilia 2008, 14:1122-4.
    • (2008) Haemophilia , vol.14 , pp. 1122-1124
    • Martinowitz, U.1    Lalezari, S.2    Luboshitz, J.3    Lubetsky, A.4    Spira, J.5
  • 25
    • 73949101435 scopus 로고    scopus 로고
    • Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A
    • Available at: Accessed September 30, 2009
    • Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A. http://clinicaltrials.gov/ct2/show/NCT00623727, Available at: Accessed September 30, 2009
  • 26
    • 2342666603 scopus 로고    scopus 로고
    • An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
    • Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003, 1:1966-71.
    • (2003) J Thromb Haemost , vol.1 , pp. 1966-1971
    • Gale, A.J.1    Pellequer, J.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.